Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

NCT05963217 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory CD19+ B-cell Lymphoma
Relapsed or Refractory Chronic Lymphocytic Leukemia
Relapsed or Refractory Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: TBI-2001
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

University Health Network, Toronto

Collaborators

[object Object]